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Abstract: Spaceflight-associated neuro-ocular syndrome (SANS)
describes a series of morphologic and functional ocular changes in
astronauts first reported by Mader and colleagues in 2011. SANS is
currently clinically defined by the development of optic disc edema
during prolonged exposure to the weightless (microgravity) envi-
ronment, which currently occurs on International Space Station
(ISS). However, as improvements in our understanding of the
ocular changes emerge, the definition of SANS is expected to
evolve. Other ocular SANS signs that arise during and after ISS
missions include hyperopic shifts, globe flattening, choroidal/retinal
folds, and cotton wool spots. Over the last 10 years, ~1 in 3 astro-
nauts flying long-duration ISS missions have presented with ≥ 1 of
these ocular findings. Commensurate with research that combines
disparate specialties (vision biology and spaceflight medicine), les-
sons from SANS investigations may also yield insight into ground-
based ocular disorders, such as glaucomatous optic neuropathy that
may have the potential to lessen the burden of this irreversible cause
of vision loss on Earth.
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S paceflight-associated neuro-ocular syndrome (SANS)describes a series of morphologic and functional ocular
changes in astronauts first reported by Mader et al.1 This
was previously referred to as visual impairment and intra-
cranial pressure (VIIP) syndrome because the presentation
of available data was similar to terrestrial intracranial
hypertension. However, because astronauts do not have
documented irreversible central visual acuity loss (hyperopic
shift is correctable) and because pathologically elevated
intracranial pressure (ICP) remains unclear, the National
Aeronautics and Space Administration (NASA) decided
that SANS was a better descriptor of the changes in
astronauts. Commensurate with research that combines
disparate specialties (vision biology and spaceflight medi-
cine), lessons from SANS investigations may also yield
insight into ground-based ocular disorders such as glau-
comatous optic neuropathy that may have the potential to
lessen the burden of this irreversible cause of vision loss
on Earth.
SANS
SANS is currently clinically defined by the develop-
ment of optic disc edema during prolonged exposure to the
weightless (microgravity) environment, which currently
occurs on International Space Station (ISS) (Fig. 1). How-
ever, as improvements in our understanding of the ocular
changes emerge, the definition of SANS is expected to
evolve. Other ocular SANS signs that arise during and after
ISS missions include hyperopic shifts, globe flattening,
choroidal/retinal folds, and cotton wool spots (Fig. 1). Over
the last 10 years, approximately one in 3 astronauts flying
long-duration ISS missions have presented with ≥ 1 of these
ocular findings. However, it is important to note that no
irreversible functional change has been documented during
long-duration spaceflight (up to 6 months). Thus far visual
acuity is correctable with corrective lenses during space-
flight. Visual field testing has not shown reproducible visual
field defects in returning astronauts. However, visual fields
may not detect subtle changes present during postflight
testing, and therefore, long-term follow-up of astronauts is
warranted.3 Again, this was one of the reasons that moti-
vated the name change from VIIP to SANS. To gain more
insight, electrophysiological testing targeting the pattern
electroretinogram4 and photopic negative response5 of the
ganglion cell are planned as part of future NASA-funded
research studies. Thus, as NASA has limited experience with
long-duration space missions, it may take some time to
understand if there are any long-term functional changes to
astronaut vision.
Multiple mechanisms have been hypothesized for
causing SANS, including increased ICP, cephalad fluid
shifts, radiation exposure retinopathy, and hypercapnia.
Among these, increased ICP is a well-known cause of disc
edema on Earth, but there have been no direct measures
of ICP during spaceflight, and preflight comparator lum-
bar puncture ICP measures have not been conducted.6
A handful of lumbar punctures have been performed during
the postflight period when astronauts were readapting to a
gravitational environment.1 These were on the higher end of
normal or only moderately elevated (22, 21, 28.5, and
28 cmH2O). Consequently, the interpretation of these data
is challenging. Future studies plan to directly measure
lumbar puncture ICP before and after spaceflight and to
determine if a relationship exists with the manifestation ofDOI: 10.1097/IJG.0000000000001293
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ocular changes in flight (https://taskbook.nasaprs.com).
Thus, among the other hypotheses, the focus of several
research investigations thus far has been on the fluid shift
hypothesis.
FLUID SHIFT HYPOTHESIS AND IOP
Lack of gravity causes fluids shifts. On Earth, body
fluids are exposed to gravity and thus the upright posture
has associated hydrostatic pressure from head to toe, with
higher pressures at the lower extremities during upright
posture, as compared with the level of the eye. In space and
during weightlessness, the removal of the gravitational
gradient leads to a headward shift of fluids, resulting in
altered local tissue fluid pressures (Fig. 2).8 Given that
astronauts are unable to “stand up” during spaceflight, the
headward fluid shift creates a constant and chronic stimulus
that has been hypothesized to be a primary contributing
factor to the development of optic disc edema. Thornton
used a stocking plethysmograph to document ~2 L of fluid
movement from the legs to the thorax during spaceflight.9
Upon entering weightlessness, astronauts reported symp-
toms of “space adaptation syndrome,” including facial
edema, headaches, and dizziness.10 Furthermore, the lack of
a gravitational gradient not only shifts fluid towards the
head but also decreases the fluid volume in the limbs.9 On
Earth, this concept is consistent with limb elevation above
heart level as a method to reduce limb edema for various
medical conditions.11 Ultrasound images of the internal
jugular vein of astronauts during short-duration spaceflight
demonstrated a 40% increase in the cross-sectional area
relative to the seated posture on Earth.12 Similarly, during
long-duration ISS missions, internal jugular vein volume
increased by as much 200% compared with preflight supine
values.13 Taken together, these results demonstrate a robust
spaceflight-induced cephalad fluid shift, but what role this
plays in the pathophysiology of SANS remains an active
part of multiple investigations.
Theoretically, the cephalad fluid shift that develops in
weightlessness from microgravity should cause IOP to
increase as a result of increased episcleral venous pressure as
dictated by the Goldman equation (see the RELEVANCE
TO EARTH EYE DISEASE section). Acute weightlessness
induced for ~20 to 30 seconds of parabolic flight does cause
~7 mmHg increase in IOP.14 Similarly, after 25 minutes of
weightlessness during the 8-day manned German Spacelab
Mission, IOP increased by ~5mmHg,15 which was similar
to the 4 to 7mmHg increase observed during the first day
on 6 Space Shuttle missions.6 However, IOP then normal-
ized after the first 4 days of spaceflight to values observed
before the flight in the seated posture.6 During the German-
Russian MIR 10-day Spacelab D2 mission, IOP measure-
ments were performed 15 minutes after launch and also
demonstrated that IOP increased from baseline values of 10
FIGURE 1. A, Photograph of disc edema after spaceflight. This finding defines spaceflight-associated neuro-ocular syndrome. B, Ultra-
sound showing optic nerve sheath dilatations and posterior globe flattening (arrows). C, Photograph showing choroidal folds (black
arrow) and cotton wool spot (white arrow). D, Total number of US Astronauts tested for each ocular variable (blue) and the number
demonstrating the finding through 2017. Optic disc edema defined as Frisèn Scale grade ≥1 from postflight fundoscopy images;
choroidal folds visualized on fundoscopy images and/or optical coherence tomography B-scans when available; globe flattening on the
basis of a subjective call from either magnetic resonance imaging or ocular ultrasound images; refractive error shift on the basis of pre to
postflight change in cycloplegic refraction ≥0.75 D; cotton wool spot observed on fundoscopy images during or after spaceflight.
Images adapted from Mader et al.1,2 Adaptations are themselves works protected by copyright. So in order to publish this adaptation,
authorization must be obtained both from the owner of the copyright in the original work and from the owner of copyright in the
translation or adaptation.
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(OD) and 10mmHg (OS) to 23 (OD) and 22 mmHg (OS)
within the first 24 hours of the mission.16 Again, IOP values
returned to preflight baseline values by the fourth day of
spaceflight.16 IOP measured during long-duration space-
flight suggests it remains similar to preflight values
throughout the duration of the mission.6 After the return
from long-duration spaceflight, IOP values were similar to
preflight measures (10 to 14 vs. 10 to 16mmHg, respec-
tively).1 Thus, currently published data suggest that there is
an immediate increase in IOP upon entering weightlessness,
but that it normalizes to ground-based levels after a few
days of flight. Chronically elevated IOP is not observed in
astronauts during long-duration ISS missions. However, this
normalization of IOP during spaceflight seems to occur
despite a sustained cephalad venous fluid shift. These data
suggest that a compensatory mechanism normalizes IOP,
but this process is not yet fully understood. Moreover,
because spaceflight-induced IOP changes seem to be on the
order of ~5 mmHg, future systematic investigation of IOP
on ISS should use an IOP device that has high sensitivity.
On Earth, the effect of an acute cephalad fluid shift on
IOP is well documented,17–22 reproducible, and inves-
tigations regarding IOP in SANS research may provide
insights into Earth-bound diseases. Indeed, inducing a
cephalad fluid shift on Earth by assuming a supine or head-
down tilt (HDT; ~6 to 15 degrees) body position shifts fluids
towards the head as the head moves below the hydrostatic
indifference point, causing an increase in IOP. It is believed
that this acute posture change causes an increase in epis-
cleral venous pressure (EVP), and this has been measured
in the supine position.23 The magnitude of IOP increase
can be remarkable (~40 mmHg in vertical head-down
suspension)24 with associated diminished retinal electro-
physiological responses.24,25 Thus, IOP change during
supine sleep is likely explained in-part by alteration in body
position,18 and spaceflight data suggest that if this increase
FIGURE 2. A, Preflight on Earth (1G) arterial blood pressure at the head is ~70mmHg, however, the pressure at the feet is 200mmHg.
During microgravity, it is hypothesized that arterial blood pressure from head to foot is similar because of the absence of the hydrostatic
pressure gradient. Postflight (1G), without the use of countermeasures, blood volume is reduced from preflight levels resulting in reduced
blood pressure at head level (figure adapted from Zhang and Hargens).7 B, On Earth, gravity directs body fluid towards the lower
extremities in upright positions but towards the head in head-down tilt position. During weightlessness, in the microgravity environment
of space, cephalad fluid shift is seen even in upright positions. Proposed countermeasures theoretically combat this. Lower-extremities
cuffs block cephalad fluid flow under weightlessness (blue line with blunted head). Lower-body negative pressure chambers draw fluid to
the lower extremities. Impedance threshold devices draw fluid into the head and in the thoracic cavity. Blue arrows denote overall body
fluid flow. Adaptations are themselves works protected by copyright. So in order to publish this adaptation, authorization must be
obtained both from the owner of the copyright in the original work and from the owner of copyright in the translation or adaptation.
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were sustained, then the normal healthy response would
be to normalize IOP. Understanding this normalization
mechanism may prove useful for better treating glaucoma
patients with chronically elevated IOP. Understanding the
regulation of IOP during posture changes and in healthy
astronauts during prolonged weightlessness may provide
new insight into the long-debated role of body position IOP
elevation in glaucoma.
SANS STUDIES USING HDT
(CHRONIC AND ACUTE)
On Earth, HDT (chronic and acute) has been used to
study fluids shifts and to replicate, study fluid shifts and to
replicate, study, and develop countermeasures against many
of the physiologic changes that occur in weightlessness.26
However, until recently, SANS findings have not been
observed using this spaceflight analog.27 Previous bed rest
studies allowed subjects to lift their head and upper torso
during meals, and prop their head up using a pillow
throughout the day and night.27–29 This may have led to
differences in the headward fluid shift compared with that
which occurs during weightlessness. Further, as the environ-
ment failed to fully replicate the mild elevation in CO2 levels
that exist on ISS, a recent bed rest study was designed to limit
lifting the head and to include a mild CO2 environment. For
the first time, use of strict HDT bed rest for 30 days in a mild
hypercapnic environment (3.8mmHg ambient PCO2) induced
Frisèn grade30 1 or 2 optic disc edema in 5 of 11 healthy test
subjects.31 OCT images were used to quantify an average
increase in the total retinal thickness of 39 µm around the
nerve after 30 days of HDT bed rest.31 This was a ~4 to 5 times
greater change than what has been observed after 70-day HDT
bed rest with a standard pillow in a normal ambient
environment.27 Six months after completion of the trial, Frisèn
grade optic disc edema resolved in all cases (personal com-
munication, Steven Laurie). Thus, this study was critically
important because it created the first model of “reversible”
human optic disc edema that could be used to study SANS
and develop potential countermeasures for use during
spaceflight. The incidence of optic disc edema during spaceflight
is 16% and frequently presents with folds; however, during
bedrest, 50% of the subjects presented with optic disc edema
but none of the subjects developed folds (S. Laurie, personal
communication, 2019). Therefore, it remains to be determined if
the mechanism underlying optic disc edema during bed rest is
exactly the same as that which occurs during spaceflight. Future
research remains necessary to understand multiple outstanding
questions, including intravenous retinal angiography to look
for disc leakage, optical coherence tomography angiography
(OCTA) to investigate microvascular alternations, and electro-
physiological assessment of ganglion cells to determine if func-
tional changes develop concurrently with the observed structural
changes.
As SANS-like changes have only begun to be observed
in chronic HDT, acute (short term) HDT has been useful to
evaluate various SANS countermeasures. One counter-
measure is lower body negative pressure (LBNP) which is a
technique that applies a vacuum to the lower extremities to
shift fluid away from the central circulation.19 Although
effective at translocating fluid, LBNP tethers the crew to a
single location in a spacecraft and requires continuous car-
diovascular medical monitoring to ensure syncope does not
develop, making this countermeasure operationally chal-
lenging to implement.
Venoconstrictive thigh cuffs (VTC) are another coun-
termeasure that applies pressure over the femoral vein to
trap venous blood in the legs as a means of shifting fluid out
of the upper body (Fig. 3). VTCs have been used by Russian
Cosmonauts to combat space adaptation syndrome and
reduce symptoms of “head congestion.”32 Although these
alone may not be as successful at moving as much fluid as
LBNP, they do allow the crew to move freely about the
spacecraft while completing other activities for extended
periods of time and do not require continuous car-
diovascular monitoring, making them more operationally
desirable.
At an average systemic blood pressure of 120/
80 mmHg, mean arterial pressure (MAP) is ~90 mmHg.
Thus, with single leg VTCs compressing at 50 to 60mmHg,
FIGURE 3. A, Photograph of Russian Bralset venoconstrictive thigh cuff device. B, Photograph of pneumatic venoconstrictive thigh cuff
device. C, Photograph of mobile venoconstrictive thigh cuff device with modified width and variable pressure adjustment mechanism.
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there is not enough pressure to block arterial blood flow into
the lower extremities, but there is enough pressure to com-
press venous beds to diminish venous return to the upper
body. In support of these approaches, the “Medical Flight”
1994 to 1995 experiments on the Mir space station demon-
strated that use of VTCs reduced jugular vein cross-section
area by 12% to 20%.33,34 Use of VTCs in ground-based
studies has demonstrated similar results of decreased inter-
nal jugular vein (IJV) diameter as well as effects on the
femoral vein.35
Currently, 2 additional types of VTCs are under
investigation. A pneumatic VTC uses an electrically driven
pump to inflate a bladder to set the pressure that is auto-
matically maintained (Fig. 3). The advantage is the ability
to deliver precise and constant pressure, and the dis-
advantage is an electrical requirement tethering astronauts
to a power source. Mobile VTCs also exist and compress the
upper thigh using micro- and macro-manipulators which
tighten and lock the cuff (Fig. 3). Theoretically, this should
provide even greater mobility, however, a disadvantage is
that it currently lacks automatic feedback mechanisms to
maintain a steady compression.
Because the goal of VTCs or LBNP is to translocate
fluid away from the head through the venous system and
thereby reduce venous pressure at the level of the eye, the
effectiveness of these countermeasures can be quantified by
studying alterations to the eye that come from acute HDT.
The application of LBNP during HDT has been shown to
significantly lower IOP by ~2mmHg,19 and we have shown
the ability of both VTCs to reverse the increased IOP and
subfoveal choroid thickness that develop during HDT.20
Preliminarily, OCTA has also documented foveal avascular
zone shrinkage in the HDT position that was partially
reversed with VTCs.36 Therefore, ocular endpoints like IOP
exist for body position alteration-induced acute fluid shifts,
and they have been useful to assess potential counter-
measures on Earth. However, it is important to state again
that acute HDT differs from the presumably mild chronic
cephalad fluid shift experienced by astronauts on the ISS.
Thus, the real purpose of these studies is to identify candi-
date countermeasures on Earth that could effectively reverse
a headward fluid shift at the level of the eye before future
studies are conducted during spaceflight.
RELEVANCE TO EYE DISEASE ON EARTH
Although these studies are illuminating for under-
standing and preventing SANS, they also offer potential
insight into Earth-bound diseases. For example, the obser-
vation that VTCs partially reversed acute HDT-induced
IOP elevation20 may have relevance for glaucoma by raising
the complex relationship between ICP, IOP, ocular blood
flow, and body position.
There may be a role for ICP in the pathophysiology of
SANS and glaucoma, however, the narrative is complex.
Again, initially, the signs and symptoms of SANS suggested
that ICP may be the initiating factor. However, with
ground-based and ISS research studies complete or near
completion, well-controlled and quantitative data suggest
that elevated ICP may not be significant or at most just one
of the potential pathophysiological mechanisms. This
encouraged the name change from VIIP to SANS.37 In
glaucoma, the interplay between IOP and ICP has also
gained recent attention because of both retrospective38 and
prospective39 observations that glaucoma patients have
decreased ICP.38 Thus, decreased ICP (or increased IOP) to
cause an increased translaminar pressure gradient has been
postulated as an additional risk factor in glaucoma. Of
course, the difference between glaucoma and SANS is the
opposite speculated direction for ICP change. However, if
research in either field can yield improved and potentially
noninvasive ways to measure ICP or translaminar pressure
gradient, this becomes an example of how investigation in 1
discipline could help the other.
Considered alone, many pivotal studies have shown that
elevated mean IOP is a very important risk factor for glau-
comatous optic nerve progression.40–44 However, the mechanism
behind IOP elevation damaging the nerve is not fully under-
stood. Mechanical mechanisms have been proposed related to
the pressure that is exerted on the nerve in addition to the sup-
port (or lack thereof) of nerve fibers traversing the lamina
cribosa.45,46 In contrast, blood flow theories hold that elevated
IOP diminishes the ocular perfusion pressure (OPP) gradient.47,48
OPP is the difference between the arterial pressure entering the
eye and the IOP that pushes back against this. With no method
to directly measure OPP, it is assessed during clinical research as
the difference between adjustedMAP and IOP (OPP = adjusted
MAP–IOP) (Table 1). Adjusted MAP is obtained from blood
pressure taken at the upper arm followed by a mathematical
correction to try to account for the distance between the arm and
eye (see below). Thus, one hypothesis is that decreased OPP may
cause glaucomatous optic nerve progression due either to high
IOP or low arterial blood flow entering the eye.
The true importance of OPP is unclear, but the concept
is tantalizing because of its constituent components. The risk
factor of IOP in glaucoma is well known. Low blood pres-
sure has also been associated with glaucomatous optic
neuropathy.47,50,51 However, attempts to directly link cal-
culated OPP to glaucoma have been very difficult. First, the
adjusted MAP is obtained from routine systemic blood
pressure measurements at the arm. As the eye is > 1 foot
away from the arm, equations have been devised to estimate
the arterial pressure entering the eye (adjusted MAP)
(Table 1). These equations are nuanced by body position
because in a vertical position, the eye is above the arm, and
when supine, the arm and eye are at equal levels.
With all of this in mind, the weaknesses of this overall
OPP approach are significant. Imagine for a moment this
scenario. A theoretical eye drop medication enters the eye,
traverses the vitreous, and actually alters the retinal or optic
TABLE 1. MAP Calculations and Adjustments
Parameter and Body Position Equation
MAP Diastolic BP+
(systolic BP–diastolic BP)/3
Adjusted MAP for arterial
pressure at eye (seated)
(0.66×MAP)
Adjusted MAP for arterial
pressure at eye (supine)
(0.88×MAP)
Adjusted MAP for arterial
pressure at eye
(head-down tilt)
MAP+7
BP indicates blood pressure; IOP, intraocular pressure; MAP, mean
arterial pressure.
Adapted from Liu et al49 and Zhang and Hargens.7
Adaptations are themselves works protected by copyright. So in order to
publish this adaptation, authorization must be obtained both from the owner
of the copyright in the original work and from the owner of copyright in the
translation or adaptation.
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nerve vasculature to bring additional blood flow into the eye.
The drug improved arterial perfusion and thus improved OPP
without directly altering IOP. In this case, there is only 1 way to
experimentally observe this finding using the above methods.
The eye drop has to increase systemic blood pressure measured at
the arm. This is obviously nonsensical, difficult to achieve, and
not the actual goal.52 Therefore, improving OPP through the
arterial component of the equation is hard because the proper
tools do not yet exist to demonstrate it at the level of the eye. In
the future, new vasculature assessment methods such as OCTA
may be useful.53–55
Improving OPP by altering IOP is more straightfor-
ward. It can be argued that this is exactly what is done every
day in glaucoma clinics through the use of eye drops
(prostaglandins and aqueous suppressants) to lower IOP.
This is where HDT studies offer additional insights.20 As
discussed above, acute HDT led to increased IOP which
could be considered deleterious. This risk is unclear though
because HDT also increases passive arterial blood flow into
the eye on the basis of gravity (see above adjusted MAP
equations). Therefore, gravity’s simultaneous elevation of
IOP and ocular arterial blood flow could theoretically
negate each other and result in minimal to no net alteration
to OPP. This is also why it is unclear if solely taking a supine
position at night is necessarily harmful in glaucoma despite
increased IOP. However, VTCs (the SANS countermeasure
discussed above) lowered IOP irrespective of body position
(HDT-VTC IOP < HDT IOP) effectively decoupling IOP
(and EVP) from blood flow despite body position change.
It is important to appreciate that VTCs in SANS
countermeasures research were not designed to treat glau-
coma. For many patients on Earth, they are not only Earth-
bound but literally bed-bound because of the inability to
regulate total body volume as a result of diseases such as
cardiomyopathy. Regardless of the cause (dilatory, hyper-
trophic, or restrictive),56 lack of cardiac forward flow can
lead to pulmonary and lower extremity edema. In such
cases, passive limb elevation or simple compressive stock-
ings are used to facilitate venous return to the central cir-
culation. This is opposite to what VTCs are intended for.
Further, by slowing down venous blood flow, the theoretical
risk of lower-extremity thrombus formation exists. Thus, the
goal should not be to give every glaucoma patient VTCs but
instead to understand the actual mechanisms through which
FIGURE 4. Episcleral veins. Aqueous angiography introduces fluorescent tracers into the eye followed by angiographic imaging in live
human subjects, here undergoing routine clinically indicated cataract surgery. Rows (A–C) show episcleral venous patterns from 3 eyes
from 3 live patients. Each row is 1 subject. Segmental patterns are seen showing regions with (green arrows) and without (red arrows)
angiographic signal. It is these episcleral veins which may be impacted by body position to alter intracranial pressure or be a target for
intracranial pressure lowering using cytoskeletal relaxing agents. Figure reproduced from Huang et al’s62 study with permission from
author.
J Glaucoma  Volume 28, Number 8, August 2019 SANS, IOP, and Glaucoma
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved. www.glaucomajournal.com | 761
Copyright r 2019 Wolters Kluwer Health, Inc. All rights reserved.
VTCs lower IOP. Here it seems that VTCs work by mod-
ulating EVP, and now new innovative ways can be consid-
ered to achieve the same endpoint.
The import of EVP in IOP regulation is gaining trac-
tion. IOP is determined by a balance between aqueous
humor production (flow into the eye) and aqueous humor
outflow (AHO) through the conventional and unconven-
tional pathways. This process is best modeled by the
modified Goldman equation57 where IOP= (Fin–Fout)(R)
+EVP [IOP is intraocular pressure (mmHg); Finis aqueous
production (μL/min); Fout is unconventional outflow (μL/
min); R is conventional outflow resistance (mmHg×min/
μL); and EVP is episcleral venous pressure (mmHg)]. Using
aqueous angiography, real-time AHO has been visualized
and noted to be segmental around the limbus in multiple
species including humans in both laboratory eyes and living
subjects.58–63 Aqueous angiography has demonstrated the
novel finding of dynamic AHO where regions with and
without baseline episcleral vein AHO can actually gain or
lose flow (Fig. 4).64,65 This means that there may be local
regulation of AHO at episcleral veins which in part reflects
the growing appreciation that the distal AHO pathways
(including episcleral veins) play a role in IOP and possibly
glaucoma. Moreover, future technological advances may
enable the measurement of EVP in various body postures.
Today, new FDA-approved treatments exist that may
already work by lowering EVP. Cytoskeletal relaxing agents are
a new drug class including rho-kinase (ROCK) inhibitors and
nitric oxide (NO) donors.66,67 Initially, laboratory evaluation
demonstrated that cytoskeletal relaxing agents lowered AHO
resistance.68,69 Focused on the trabecular meshwork (TM),
these drugs mechanistically impacted TM cytoskeleton, con-
tractility, and extracellular matrix to promote easier AHO.
However, long studied in other systems, NO derivatives are also
well known to vasodilate and are first-line treatments for acute
coronary syndrome and vasospastic angina.70 Decades-old
animal studies have shown that NO derivatives lower EVP in
some species as a TM-independent mechanism to lower IOP.71
During ROCK inhibitor clinical trials, up to 50% of patients
demonstrated ocular surface vessel dilation.67 Recent aqueous
humor dynamic measurements under ROCK inhibitor treat-
ment also showed statistically significant EVP reduction in
humans.72 Therefore, although undoubtedly impacting the TM,
the suggestion has also been raised as to whether cytoskeletal
relaxing agents also lower IOP through mechanisms outside or
past the TM at aqueous and episcleral veins. It is here that
SANS research supports these concepts because fluid shift
altering VTCs lowered HDT-induced IOP elevation. Now,
future innovation could be directed towards attempting to lower
IOP by redistributing fluid balance in and around the eye.
CONCLUSIONS
Human exploration, for example during the early sea
voyages, identified the previously unknown nutritional
requirement of vitamin C to prevent scurvy. Here, long-
duration spaceflight on the ISS has revealed SANS, a unique
syndrome without an Earth-based correlate and therefore
may offer new insights into the fields of vision science and
ocular biology. Potentially involving several ocular ana-
tomic compartments acutely or chronically (eg, the optic
nerve, IOP, retina, blood flow, and refraction), a multi-
disciplinary approach is required to understand and mitigate
SANS. Therefore, SANS represents a major astronaut
safety hurdle for exploration-class space missions and
further research will be needed to understand the
pathophysiology, identify additional risk factors, create
preventative countermeasures, and possibly develop treat-
ments. NASA has funded several investigations that are
ongoing or being implemented that use the chronic HDT
model and 1-year spaceflight mission on the ISS. In addi-
tion, NASA has funded several ground and flight rodent
experiments to obtain data that are difficult or impossible to
obtain in human research studies. At this point, what is clear
is that SANS is a unique disease entity and not the same as
similar Earth-based optic neuropathies such as idiopathic
intracranial hypertension. Further, research into SANS has
the potential to yield new insights into Earth-based diseases
such as glaucoma and various optic neuropathies.
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